Obinutuzumab in Marginal Zone Lymphoma

NCT03322865 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Obinutuzumab

Sponsor

Christian Buske

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]